ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of$256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and$370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjusted EBITDA(1) Expected to be$85 Million Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance During 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ADM ...